Stroke-SCORE: Personalizing Acute Ischemic Stroke Treatment to Improve Patient Outcomes

Background: /Objectives: Acute ischemic stroke (AIS) is a leading cause of disability and mortality worldwide. Despite advances in interventions such as thrombolysis (TL) and mechanical thrombectomy (MT), current treatment protocols remain largely standardized, focusing on general eligibility rather than individual patient characteristics. To address this gap, we introduce the Stroke-SCORE (Simplified Clinical Outcome Risk Evaluation), a predictive tool designed to personalize AIS management by providing data-driven, individualized recommendations to optimize treatment strategies and improve patient outcomes. Methods: The Stroke-SCORE was derived using retrospective data from 793 AIS patients admitted to the University of Pécs (February 2023 - September 2024). Logistic regression analysis identified age, National Institutes of Health Stroke Scale (NIHSS) score at admission, and pre-morbid modified Rankin Scale (pre-mRS) score as key predictors of unfavorable outcomes at 90 days (defined as modified Rankin Scale [mRS] score >2). Based on these predictors, a simplified risk score was developed to stratify patients into low, moderate, and high-risk groups, guiding treatment decisions on TL, MT, combination therapy (TL + MT), or standard care (SC). Internal validation was performed to assess the model’s predictive performance via receiver operating characteristic (ROC) analysis and isotonic regression calibration with bootstrapping. Results: The Stroke-SCORE was moderately positively correlated with a 90-day mRS score >2 (correlation coefficient: 0.51, p < 0.001), with an area under the curve (AUC) of 0.86, a sensitivity and specificity of 79% and 81%, respectively, and an overall accuracy of 80%. Simulations indicated that personalized treatment guided by the Stroke-SCORE significantly reduced unfavorable outcomes. Conclusions: The Stroke-SCORE demonstrates strong predictive performance as a practical, data-driven approach for personalizing AIS treatment decisions. In the future, external, multicenter prospective validation is needed to confirm its applicability in real-world settings.